PREFER is a public-private research project where academic researchers, HTA, patient organisations, and the pharmaceutical industry work together to find out when, and how patients’ treatment preferences can be used in medical product development. We include patient stakeholders at every level of the project. Developing a set of recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies.
The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The publications in this Zenodo community reflects the authors’ and the PREFER project's view, and not the view of IMI, the European Union or EFPIA.